The Dermatology Digest

SEPTEMBER 12, 2024

“The positive pivotal data from this study reinforce the potential of Dupixent to offer a new treatment option for the many people suffering from chronic spontaneous urticaria who do not respond to standard-of-care antihistamines,” says Dietmar Berger, MD, PhD, Chief Medical Officer, Global Head of Development at Sanofi, in a news release.

Safety 36

Safety Office Medical Dermatology 36

North Dallas Dermatology Associates

NOVEMBER 1, 2023

One misconception is cosmetic procedures are the same everywhere, from a local spa to a board-certified physician’s office. After all, who wouldn’t want to be in the capable hands of a medical professional? Many medical spas are unable to provide medical oversight to handle complications that may arise during a procedure.

Office 36

Office Safety Medical Training 36

The Dermatology Digest

SEPTEMBER 20, 2024

Food and Drug Administration (FDA) has approved Alpha Tau Medical Ltd.’s Secondary efficacy objectives include progression-free survival, overall survival and local control up to twelve months after treatment, and the safety objective is the measurement of any related adverse events. Dr. Robert B.

Office 74

Office Safety Clinic Medical 74

Southeastern Esthetics Institute

AUGUST 23, 2016

Estheticians and consumers alike understand the advanced changes that can be made within a medical setting - and physicians are realizing the supportive role that Estheticians can bring to their practices. Working in a medical setting as an Esthetician can be both rewarding and beneficial for both yourself and your clients alike.

Esthetician 195

Esthetician Esthetics Document Office 195

The Dermatology Digest

JANUARY 20, 2024

The study is designed to assess the safety, tolerability, and pharmacokinetics, of orally administered EVO756. The Phase 1 study is a randomized, double-blind, placebo-controlled single and multiple ascending dose (SAD and MAD) study in normal healthy adults and an open-label study in adults with CSU.

Safety 74

Safety Office Dermatitis Dermatology 74

The Dermatology Digest

JULY 29, 2024

Key secondary endpoints will include PASI 90, PASI 100 and sPGA 0 measured at Weeks 16 and 24, and safety and tolerability. Patients completing Week 24 will have the opportunity to participate in a long-term extension (LTE) trial, ONWARD3, that will evaluate durability and maintenance of response and long-term safety.

Clinic 36

Clinic Safety Office Treatments 36

The Dermatology Digest

APRIL 18, 2024

The safety profile was similar across all three arms and overall, 88.9% of adverse events were rated as mild and no serious adverse events were identified. The study appears in the Aesthetic Surgery Journa l. “The The study appears in the Aesthetic Surgery Journa l.

Safety 36

Safety Office Surgery Dermatology 36

The Dermatology Digest

NOVEMBER 6, 2024

. “The new Translational Bridge Award addresses a critical gap in lupus research, enabling scientists to bring their most promising ideas closer to people living with lupus,” says Teodora Staeva, PhD, LRA Vice President and Chief Scientific Officer, in a news release.

Hospital 36

Hospital Therapy Management Networking 36

The Dermatology Digest

JANUARY 29, 2024

The STudy of Roflumilast foam Applied Topically for the redUction of seborrheic derMatitis (STRATUM) was a parallel group, double-blind, vehicle-controlled study evaluating the safety and efficacy of Zoryve (roflumilast) foam, 0.3% Zoryve foam was well-tolerated with a favorable safety and tolerability profile.

Dermatitis 74

Dermatitis Safety Dermatology Treatments 74

The Dermatology Digest

SEPTEMBER 30, 2024

The OLE results continue to show that ESK-001 has the potential to safely and effectively inhibit the TYK2 target at the 40mg twice daily dose and deliver lasting benefits that improve over time with continued treatment,” says Dr. Jörn Drappa, Alumis’ Chief Medical Officer, in a news release.

Safety 36

Safety Clinic Sustainability Office 36

New Age Spa Institute

APRIL 18, 2024

In the field of medical aesthetics, lasers are used primarily for hair removal, promoting the destruction of hair follicles and sealing off the vessels that feed hair bulbs. LASER treatments are classified as medical procedures due to their invasive nature and the specific training required to operate these powerful devices.

Legal 52

Legal Hair Removal Safety Esthetician 52

Natural Beauty Med Spa

APRIL 28, 2024

However, you might be reluctant to commit to it due to concerns about safety. The most important thing you should do is entrust yourself to a qualified aesthetic medical team. Safety is of the utmost importance to us, and we take every reasonable precaution to protect our patients. Is it worth it?

Med Spa 52

Med Spa Scarring Safety Makeup 52

The Dermatology Digest

FEBRUARY 22, 2024

The primary endpoints of the study are the proportion of SK lesions with a Physician Lesion Assessment (PLA) score of clear (PLA=0) at last visit and the safety of SM-020 gel 1.0% CT-213 is a Phase 2b randomized, double-blind, vehicle-controlled clinical trial in 60 subjects with five to ten SK target lesions treated with SM-020 gel 1.0%

Safety 36

Safety Clinic Office Hyperpigmentation 36

The Dermatology Digest

FEBRUARY 22, 2024

The primary endpoints of the study are the proportion of SK lesions with a Physician Lesion Assessment (PLA) score of clear (PLA=0) at last visit and the safety of SM-020 gel 1.0% CT-213 is a Phase 2b randomized, double-blind, vehicle-controlled clinical trial in 60 subjects with five to ten SK target lesions treated with SM-020 gel 1.0%

Safety 36

Safety Clinic Office Hyperpigmentation 36

The Dermatology Digest

FEBRUARY 8, 2024

In 2023, dermatologists and their patients welcomed new drugs for acne, psoriasis, alopecia areata, and more, and 2024 promises to deliver real-world data on these medications along with even more therapeutic innovations across the spectrum of cutaneous diseases. We will, for sure, have new medications for chronic urticaria.”

Dermatology 78

Dermatology Eczema Pharmaceutical Dermatitis 78

The Dermatology Digest

AUGUST 14, 2024

The Phase 2 trial is a 2-part, open-label, multicenter, dose-escalation, proof-of-concept study with a safety run-in designed to assess the safety and tolerability, pharmacokinetics, and efficacy of VP-315 when administered intratumorally to adults with biopsy-proven basal cell carcinoma. It’s very, very exciting data.”

Safety 36

Safety Pharmaceutical Clinic Dermatology 36

The Dermatology Digest

JANUARY 14, 2024

Zoryve foam was well-tolerated with a favorable safety and tolerability profile. As the first topical drug approved with a new mechanism of action for this condition in 20 years, foam represents an important advancement in treatment and addresses a truly significant need in this population.”

Dermatitis 72

Dermatitis Dermatology Office Safety 72

The Dermatology Digest

MAY 6, 2024

The Phase 2a trial ( NCT05984784 ) evaluates the safety, pharmacokinetics, and efficacy of IMG-007 in adult patients with moderate-to-severe AD who had inadequate response to and/or intolerant of topical therapies. Topical or systemic AD medications were not permitted during the study. and Canada. with IGA=4.

Safety 36

Safety Dermatitis Therapy Dermatology 36

Art of Dermatology

MAY 17, 2024

At Art of Dermatology at the Laser and Skin Surgery Center of New York, patient safety and satisfaction is Dr. Jessica Krant’s primary concern. Making sure you are seeing a board-certified core cosmetic specialty physician (dermatologist, plastic surgeon, oculoplastic surgeon, or ENT facial plastic surgeon) in a real medical office is key.

Office 36

Office Surgery Safety Injections 36

The Dermatology Digest

MAY 9, 2024

Data from both trials demonstrated a consistent, favorable safety and tolerability profile with no treatment-related serious adverse events (SAEs) or SAEs leading to discontinuation reported in imsidolimab-treated patients. Anaptys plans to submit a data abstract for GEMINI-1 and GEMINI-2 results to a medical meeting later this year.

Office 36

Office Safety Medical Therapy 36

The Dermatology Digest

FEBRUARY 27, 2024

. “The approval of SIMLANDI marks the first high-concentration, citrate-free biosimilar to Humira with IC status,” says Dr. Eric Hughes, Executive Vice President Global R&D and Chief Medical Officer at Teva, in a news release.

Safety 36

Safety Marketing Pharmaceutical Partnerships 36

The Dermatology Digest

JANUARY 20, 2024

The study is designed to assess the safety, tolerability, and pharmacokinetics, of orally administered EVO756. The Phase 1 study is a randomized, double-blind, placebo-controlled single and multiple ascending dose (SAD and MAD) study in normal healthy adults and an open-label study in adults with CSU.

Safety 36

Safety Office Dermatitis Dermatology 36

The Dermatology Digest

FEBRUARY 7, 2024

The total duration of the trial was up to 24 weeks, which included a four-week screening period, a 16-week treatment period and a four-week safety follow-up period. Improvements were also consistent across Patient Reported Outcomes through Week 16.

Safety 36

Safety Clinic Office Dermatology 36

The Dermatology Digest

JANUARY 24, 2024

It is a phase 3, two-arm trial (N=513) that compares the efficacy and safety of delgocitinib cream with alitretinoin capsules. No specific treatment-emergent safety concerns were identified for delgocitinib cream, and the overall safety profile was consistent with what was observed in DELTA 1, 2 and 3.

Eczema 36

Eczema Safety Office Treatments 36

The Dermatology Digest

JANUARY 14, 2024

INTEGUMENT-1 and INTEGUMENT-2 (The INterventional Trial EvaluatinG roflUMilast cream for the treatmENt of aTopic dermatitis) were two identical Phase 3, parallel-group, double-blind, vehicle-controlled trials evaluating the safety and efficacy of roflumilast cream 0.15% in AD. Fully 91.5% Importantly, EASI-90 was observed in 22.4%

Dermatitis 36

Dermatitis Safety Dermatology Hospital 36

The Dermatology Digest

MARCH 9, 2024

For the 16-week phase 2 trial study, researchers evaluated the safety and efficacy of remibrutinib in 77 adults with moderate to severe HS for at least 12 months in two or more anatomical areas with 15 or fewer tunnels beneath the skin. Only secukinumab (Cosentyx, Novartis) and adalimumab (Humira, AbbVie) have the U.S.

Office 36

Office Safety Medical Dermatology 36

Aesthetic Advancements Institute (AAI)

JUNE 20, 2023

Juvéderm’s® newest filler, Volux , has been approved by the FDA and is set to hit medical offices in early 2023. With Volux, medical professionals have a new option for providing results and increased support and structure for the cheeks, chin, and jawline.

Training 36

Training Injections Medical Facials 36

The Dermatology Digest

JANUARY 11, 2024

Storrs Medical Dermatology Professor and Director of CLEAR Eczema Center, at the Oregon Health & Science University, in a news release. Storrs Medical Dermatology Professor and Director of CLEAR Eczema Center, at the Oregon Health & Science University, in a news release. “If

Dermatitis 36

Dermatitis Safety Eczema Sensitive Skin 36

Lipgloss and Aftershave

NOVEMBER 1, 2024

Dr. Krystal Briglia, L+A Medical + Wellness Editor Dr. Krystal Briglia of Triada Integrative Medicine + Wellness is a board-certified nurse practitioner specializing in aesthetic dermatology, integrative medicine, and wellness. View this post on Instagram A post shared by News Reviews Education for Skin Pros (@lipgloss_aftershave) 5.

Chemical Peels 52

Chemical Peels Hyperpigmentation Vitamin C Microneedling 52

Trillium Creek Dermatology

JANUARY 12, 2024

Additionally, Botox can be used to treat excessive sweating, migraines, and other medical concerns. Microblading is especially valuable for patients who have lost their eyebrows due to medical concerns, but anyone who wants to adjust their eyebrow shape or add volume can benefit.

Treatments 36

Treatments Eyebrow Shaping Chemical Peels Facials 36

The Dermatology Digest

AUGUST 15, 2024

The safety of the drug product is being evaluated based on frequency of adverse events (AEs) and application site reactions (ASRs). Lesions are being treated with SM-020 1% gel twice daily for 28 days, with the primary endpoint based on percent change from baseline in greatest tumor diameter at week 6.

Clinic 36

Clinic Scarring Office Safety 36

The Dermatology Digest

FEBRUARY 13, 2024

The safety profile and overall incidence of adverse wound reactions were comparable between arms. Snyder, Chief Medical Officer of MediWound, in a news release. In those patients who achieved complete wound closure, the average time to wound closure was 48.4 days for EscharEx vs. 76.0 days for Santyl.

Safety 36

Safety Marketing Office Clinic 36

Fairlawn Aesthetic MD

MARCH 14, 2024

Simply put, semaglutide is a medication approved for weight management in adults. Why Gradual Adjustment Matters Our bodies are indeed remarkable systems that adapt to change over time, and this adaptability is something we aim to work with through a gradual increase in medication. So, what exactly is it?

Injections 36

Injections Management Medical Office 36

The Dermatology Digest

DECEMBER 20, 2023

Tim Raducha-Grace Named Chief Platform Officer at Zerigo Health Tim Raducha-Grace is the new Chief Platform Officer at Zerigo Health, a connected phototherapy platform that couples a handheld Narrow-band ultraviolet B (NB-UVB) light device with a smartphone app and team of care providers to allow patients to treat psoriasis and eczema at home.

Dermatology 36

Dermatology Surgery Eczema Office 36

US Dermatologt Partners

MARCH 27, 2024

Thus began research into the potential medicinal uses of red light therapy for a variety of health conditions, which is already widely medically accepted in its use as photodynamic therapy. Safety and Side Effects This procedure is considered safe.

Therapy 41

Therapy Treatments Dermatology Collagen 41

The Dermatology Digest

MAY 15, 2024

FDA and Japan’s Pharmaceuticals and Medical Device Agency (PMDA) on the proposed design of the Phase 3 clinical trial. COVE-1 was an open label clinical trial that evaluated the safety and efficacy of VP-102 in two cohorts of subjects with up to six warts. and Japan, including potentially within the European Union.”

Pharmaceutical 36

Pharmaceutical Clinic Sales Dermatology 36

Art of Dermatology

SEPTEMBER 29, 2022

Dr. Krant , a board-certified dermatologist with specialized experience in cosmetic, laser, surgical, and medical dermatology, is happy to serve New York City with comprehensive dermatological care. Dr. Krant’s in office peels are all superficial peels, which optimizes safety and comfort.

Chemical Peels 36

Chemical Peels Office Injections Wrinkles 36